| A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years (NCT02531698) | Pfizer | 2015-08-01 |
| Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation (NCT01890759) | Sanofi Pasteur, a Sanofi Company | 2013-06-25 |
| Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose (NCT01543087) | Pfizer | 2012-09-07 |
| Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age (NCT01659996) | Sanofi Pasteur, a Sanofi Company | 2012-07-01 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers (NCT01340898) | GlaxoSmithKline | 2012-01-27 |
| Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine (NCT01442675) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children (NCT01689155) | Sanofi Pasteur, a Sanofi Company | 2011-06-01 |
| Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations (NCT01359449) | Sanofi Pasteur, a Sanofi Company | 2011-05-01 |
| A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India (NCT01086969) | Sanofi | 2010-06-01 |
| A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers (NCT01049035) | Sanofi Pasteur, a Sanofi Company | 2009-12-16 |
| Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants (NCT00806195) | Novartis | 2008-12-01 |
| Dose Comparison Study of Menactra® in US Children (NCT00700635) | Sanofi Pasteur, a Sanofi Company | 2008-06-01 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers (NCT00631995) | Sanofi Pasteur, a Sanofi Company | 2008-04-01 |
| Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients (NCT00715234) | University of Colorado, Denver | 2007-10-01 |
| Immunogenicity of the Booster Dose of Two MenC Vaccines (NCT00392808) | Centro Superior de Investigación en Salud Publica | 2007-01-01 |
| Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® (NCT00258856) | Sanofi Pasteur, a Sanofi Company | 2006-01-01 |
| Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® (NCT00269477) | Sanofi Pasteur, a Sanofi Company | 2005-12-01 |
| Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age (NCT00310635) | Novartis | 2005-06-01 |
| Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age (NCT00643916) | Sanofi Pasteur, a Sanofi Company | 2004-12-01 |